Daily Newsletter

24 November 2023

Daily Newsletter

24 November 2023

PharmAbcine publishes preclinical data on PMC-403 for ISCLS

The antibody received FDA orphan drug designation to treat systemic capillary leak syndrome earlier this year.

Srivani Venna November 24 2023

South Korean biotechnology company PharmAbcine has published preclinical research demonstrating the potential of PMC-403, its Tie2-activating antibody programme.

PMC-403 has been tested for the treatment of idiopathic systemic capillary leak syndrome (ISCLS), also known as Clarkson disease.

ISCLS is a severe systemic rare disorder caused by the sudden exit of fluids and proteins from blood vessels into surrounding tissues when systemic vascular endothelial cells function abnormally.

The trial results highlight the therapy’s ability to reduce vascular leakage associated with ISCLS in the preclinical models.

PMC-403 has a novel mechanism of action that activates the Tie2 receptor while normalising the pathological blood vessels that leak.

Earlier this year, the antibody received orphan drug designation (ODD) from the US Food and Drug Administration (FDA) to treat systemic capillary leak syndrome.

PharmAbcine conducted the trial in partnership with NIH's Lung and Vascular Inflammation Section chief Dr Kirk Druey.

It was observed that PMC-403 improved survival and alleviated vascular leakage in the mouse model of ISCLS induced by histamine.

The trial has extended to treat mice exposed to influenza, showing favourable data in reducing vascular leakage.

PharmAbcine president and CEO Dr Jin-San Yoo said: “This study provides vital insights into the efficacy and potential expandability of Tie2-activating antibody for vascular diseases.

“Leveraging these preclinical data and the ODD grant by the US FDA, we are highly committed to seeking collaborative clinical research partnerships to expedite the development of an ISCLS therapy.”

PMC-403 is also being trialled for other therapeutic areas that are related to pathological vessels, including chronic kidney disease and vessel-related rare disease.

In May this year, PharmAbcine received Korean Ministry of Food and Drug Safety (MFDS) approval for its investigational new drug application for PMC-403.

This approval allowed the company to begin a Phase I clinical trial of PMC-403 for neovascular age-related macular degeneration.

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close